Cambridge-based Qureight has closed a $20 million Series B financing round led by Molten Ventures, with participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension. The round brings total funding to over €27 million.

What Qureight Actually Does

Qureight operates as an end-to-end imaging company focused on clinical trials for lung and heart disease. Its platform sits at the intersection of contract research organization (CRO) services and AI-driven analytics — a combination that's increasingly attractive to biopharma companies that need faster, more precise trial endpoints.

The platform comprises three core components:

  • Global imaging CRO services — managing image handling, site onboarding, and patient inclusion decisions across trials
  • Proprietary AI lung image biomarkers — quantifying compartment-specific structural changes that signal disease progression
  • Data science products — including synthetic control arms that allow comparisons to real trial arms, cutting both study costs and duration

The company is also building a dedicated AI imaging laboratory to house its 3D chest imaging Foundation Model, which it says significantly reduces the data volume and time required to develop new disease models.

Where the Capital Goes

The Series B will fund expansion into four new disease areas: asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. These sit alongside Qureight's established models in lung fibrosis, widening the addressable market and reinforcing its pitch as a disease-agnostic platform.

"Expanding the company's 3D imaging deep learning models with its new AI laboratory will complement our existing dominance in lung fibrosis, allow it to enter new markets, and solidify its leadership position in the lung and heart imaging CRO market." — Dr Muhunthan Thillai, Co-founder and CEO, Qureight

The round also brings governance changes: Dr Inga Deakin, Partner at Molten Ventures, joins the Board of Directors, as does Anna Salim of Hargreave Hale.

Why This Matters for the AI-in-Healthcare Narrative

Qureight's approach is notable because it's not trying to replace clinicians or automate diagnosis — it's targeting the clinical trial pipeline itself, where imaging inefficiencies create real delays and cost overruns for biopharma sponsors.

"Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team's rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation." — Dr Inga Deakin, Partner, Molten Ventures

Synthetic control arms, in particular, are gaining traction across the industry as a way to reduce the size and duration of trials — especially in rare diseases where patient recruitment is a bottleneck. Pairing that with precision imaging biomarkers positions Qureight in a niche that's technically defensible and commercially well-timed.

Implications for Founders and Investors

For founders building in applied AI, Qureight's trajectory illustrates a few things worth noting:

  • Vertical depth beats horizontal breadth at early stages — Qureight built dominance in a single disease area (lung fibrosis) before expanding
  • Regulatory compliance as a moat — the company explicitly markets its platform as regulatory-compliant, which is a significant barrier to entry in clinical settings
  • Foundation models as infrastructure — building a proprietary 3D imaging Foundation Model creates compounding advantages as new disease models are layered on top

The broader market context supports the raise: AI-powered clinical trial optimization is attracting serious capital, with players like Medidata (Dassault Systèmes), Veeva, and a wave of startups competing to modernize trial infrastructure. Qureight's differentiation lies in imaging specificity and its integrated CRO service layer — a combination that pure software vendors can't easily replicate.